ArticleAnnals of surgical oncology2025
Favorable Response Defined by CA19-9 Reduction After Neoadjuvant Treatment for Pancreatic Cancer.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Surgical Perspectives on Neoadjuvant Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer.Cancers · 2026Review
- Surgical decision-making in borderline resectable pancreatic cancer in the era of neoadjuvant therapy: from response assessment to individualized operative strategy.Frontiers in surgery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundNeoadjuvant treatment (NAT) for pancreatic cancer has been shown to reduce mortality risk, with carbohydrate antigen (CA)19-9 response indicating survival outcomes. The purpose of this study is to clarify the degree of the CA19-9 response after neoadjuvant treatment (NAT) on prognosis. PATIENTS AND
methodsIn this retrospective, multicenter, observational study involving 1811 patients with pancreatic cancer scheduled for surgery, patients were stratified on the basis of pretreatment CA19-9 levels into elevated CA19-9 level and CA19-9 within the normal range groups. The groups were further divided into upfront surgery (UPS) and NAT subgroups.
resultsPatients with high CA19-9 levels had significantly poorer prognoses compared with those with normal levels. Among the high CA19-9 group, patients undergoing NAT demonstrated significantly improved prognoses compared with those receiving UPS. Further analysis of the high CA19-9 and received NAT group stratified by CA19-9 response showed clearly different median survivals: normalized CA19-9 group > decreased but not normalized CA19-9 group > increased CA19-9 after NAT group. Notably, patients with post-NAT CA19-9 levels < 296 U/mL (eightfold of upper limit) and > 40% reduction in CA19-9 levels had equivalent prognoses as those with normalized CA19-9 levels, while those with post-NAT CA19-9 levels > 296 U/mL and/or < 40% reduction in its value had a worse prognosis, akin to those with increased CA19-9 after NAT.
conclusionsNAT improves the prognosis of patients with pancreatic cancer with high CA19-9 levels, allowing for clear stratification of patients into favorable responders, defined as those with post-NAT normalized CA19-9 or levels < 296 U/mL with a > 40% reduction in CA19-9, and unfavorable responders.
Indexed as
Identifiers
40890542What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.